focus -WSS

focus

author：explore 2025-09-27 23:51:37 - browse：91896

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Ending racial health disparities hinges on penalties, political will

explore

WSS

Why Congress must ban federal programs from using QALYs

EF3 tornado rips through North Carolina amid extreme weather nationwide

How climate

I learned firsthand about improving diversity in clinical trials

Hospital price transparency does save money, advocate argues

How climate

entertainment

focus

focus

Bright Health sells Medicare Advantage business to Molina

Beam Therapeutics to lay off 20% of its staff, re

Medical records are filled with copy

Medicare reduced heart disease by changing how it pays doctors

Guidelines to prevent youth baseball injuries need more muscle

UnitedHealth’s board chair also owns a personal investment firm

Heart attack and stroke risk calculators need revising

Texas Department of Public Safety speaks out on migrant abuse allegations

Duchenne breakthrough therapy leaves behind pioneering families

Vir antibody drug aimed at influenza A fails in clinical trial

leisure time

Tocagen's brain cancer gene therapy trial continues. Investors worry

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

Beam Therapeutics to lay off 20% of its staff, re

The EU Joint Clinical Assessment needs to live up to its promise

STAT Summit: Biotech founders on deal

I learned firsthand about improving diversity in clinical trials

explore

Wikipedia

explore

entertainment